Inogen Inc (INGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inogen Inc (INGN) has a cash flow conversion efficiency ratio of -0.037x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.68 Million) by net assets ($182.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INGN company net worth for the company's overall valuation and market capitalisation.
Inogen Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Inogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inogen Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Inogen Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DAE HWA Pharmaceutical Co. Ltd
KQ:067080
|
-0.020x |
|
Dynacons Systems & Solutions Limited
NSE:DSSL
|
0.031x |
|
Userjoy Technology Co Ltd
TWO:3546
|
0.066x |
|
Austral Resources Australia Ltd
AU:AR1
|
-0.593x |
|
Chunil Express
KO:000650
|
0.001x |
|
Pantech Group Holdings Bhd
KLSE:5125
|
-0.017x |
|
Genesis Land Development Corp.
TO:GDC
|
0.064x |
|
Friedman Industries Inc. Common Stock
NYSE MKT:FRD
|
0.003x |
Annual Cash Flow Conversion Efficiency for Inogen Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Inogen Inc from 2011 to 2025. View Inogen Inc (INGN) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $192.23 Million | $-11.22 Million | -0.058x | -271.53% |
| 2024-12-31 | $173.86 Million | $5.91 Million | 0.034x | +315.43% |
| 2023-12-31 | $204.81 Million | $-3.23 Million | -0.016x | +87.49% |
| 2022-12-31 | $297.41 Million | $-37.53 Million | -0.126x | -297.70% |
| 2021-12-31 | $370.23 Million | $23.63 Million | 0.064x | -39.70% |
| 2020-12-31 | $349.62 Million | $37.01 Million | 0.106x | -10.12% |
| 2019-12-31 | $344.62 Million | $40.59 Million | 0.118x | -39.04% |
| 2018-12-31 | $310.42 Million | $59.98 Million | 0.193x | -27.49% |
| 2017-12-31 | $227.04 Million | $60.49 Million | 0.266x | +56.33% |
| 2016-12-31 | $182.09 Million | $31.03 Million | 0.170x | -40.15% |
| 2015-12-31 | $134.02 Million | $38.16 Million | 0.285x | +114.33% |
| 2014-12-31 | $118.15 Million | $15.70 Million | 0.133x | -44.46% |
| 2013-12-31 | $56.30 Million | $13.47 Million | 0.239x | +70.71% |
| 2012-12-31 | $28.57 Million | $4.00 Million | 0.140x | -43.05% |
| 2011-12-31 | $7.56 Million | $1.86 Million | 0.246x | -- |
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen the… Read more